Post-earnings recap
Reported
Mon, Nov 7, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations, Ultragenyx Pharma's stock rose by nearly 6% following the earnings report. This positive reaction may be attributed to management's optimistic outlook on their pipeline and operational strategies. Investors seem to be encouraged by the company's commitment to growth, even in the face of a loss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.64 | N/A | -4.93% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of determination to push forward with their development programs. They acknowledged the challenges but expressed confidence in their long-term strategy.
Management emphasized their commitment to advancing their pipeline despite the EPS miss.
They noted ongoing efforts to enhance operational efficiency.